Interleukin-1 pathway (IL-1 pathway)

The **Interleukin‐1 pathway** refers to the network of molecular interactions initiated by members of the interleukin‐1 family—a group comprising at least eleven cytokines including **interleukin‐1 alpha** (*IL‐1α*), **interleukin‐1 beta** (*IL‐1β*), their natural antagonist (**IL‐１Ra**), and related molecules such as *IL‐18*, *IL‐33*, and others. These cytokines bind to specific cell surface receptors—primarily **interleukin–１ receptor type I** (*IL–１RI*)—and recruit accessory proteins like *IL–１RAcP* to form active complexes that trigger intracellular signal transduction cascades. The main function is regulation and amplification of inflammatory responses following tissue injury or infection through activation of downstream pathways involving adaptor proteins such as MyD88, leading ultimately to gene expression changes that drive inflammation, fever, leukocyte recruitment, and other aspects of innate immunity. Dysregulation or overactivation can result in chronic inflammation implicated in autoimmune/autoinflammatory diseases, cardiovascular disorders like atherosclerosis and pericarditis, certain cancers, dermatologic conditions, and complications during infection. Therapeutically targeting this pathway has proven effective for several indications using agents that block either the ligands themselves (*e.g.*, canakinumab for *IL–１β*, bermekimab for *IL–１α*) or their receptors (*e.g.*, anakinra). Safety concerns primarily relate to increased susceptibility to infections due to suppression of critical immune functions. The "Interleukin−１ pathway" is not a single molecule but rather encompasses multiple interacting proteins—including ligands, receptors, antagonists—and thus should be considered a canonical therapeutic target class/pathway rather than an individual drug target protein. If you require structured data on individual components within this pathway—such as "Interleukin−１ beta" or "Interleukin−１ receptor type I"—these would each have their own canonical names/entries.

Other names

IL-1 signaling pathwayInterleukin-1 family signalingIL-1 cytokine pathway

Blockade of ligand-receptor interaction to inhibit downstream proinflammatory signaling. Neutralization of specific cytokines such as IL‑1α or IL‑1β with antibodies or decoy receptors. Competitive inhibition at the receptor level by recombinant antagonists like anakinra.